Cite
MLA Citation
A. Sehgal et al.. “S258: LISOCABTAGENE MARALEUCEL (LISO-CEL) AS SECOND-LINE THERAPY FOR R/R LARGE B-CELL LYMPHOMA (LBCL) IN PATIENTS NOT INTENDED FOR HSCT: PRIMARY ANALYSIS FROM THE PHASE 2 PILOT STUDY.” HemaSphere, vol. 6, n.d., pp. 159–160. http://access.bl.uk/ark:/81055/vdc_100158013638.0x00000a